Tag - Roth

Roth Capital Partners initiated coverage of GlycoMimetics (NASDAQ:GLYC) with a “buy” rating and $25 price target. The stock closed at $10.52 on Oct. 23. “Our bull thesis on GlycoMimetics is driven by the GMI-1271...